Ex-CEO's Corvus Floats $2 Take-Private Bid for CDT Equity; Shares Close Far Below It
Andrew Regan's Corvus says it will propose $2.00 a share unless CDT's board acts on the gap to its Sarborg stake. The stock closed Friday at $1.31 on about 63 times normal volume.

Corvus Capital Ltd., beneficially owned by former chief executive Andrew Regan, said it intends to propose taking CDT Equity Inc. (NASDAQ: CDT) private at $2.00 per share. The condition is that the board fails to come up with its own plan to close the gap between the share price and the company's assets. Regan's Nov. 5 letter to CDT's directors was attached to an amended Schedule 13D filed by Corvus at 9:15 a.m. ET on Friday, Nov. 6, during pre-market trading (the session before the 9:30 a.m. open).
A Schedule 13D is the disclosure required from holders of more than 5% of a company. The letter puts the $2.00 figure at a 96.3% premium to the Nov. 4 close of $1.018. It names no financing source or timetable, and it states that it is not an offer and creates no binding obligation.
A conditional proposal the market only partly priced in
The stock jumped but closed Friday at $1.31, well below the $2.00 Corvus named. That gap suggests traders put heavy odds on the proposal never becoming a deal. According to the letter, any transaction would need due diligence, definitive agreements, a recommendation from the independent directors, and shareholder, Sarborg and regulatory approvals.
Early gains faded through the day
Part of the move came before the letter was public. CDT rose 13.95% in Thursday's after-hours session (trading after the 4 p.m. close), and Nasdaq then halted the stock at 7:50 p.m. ET for pending news. Trading resumed at 9:00 a.m. Friday, before the filing posted.
- Pre-market: the stock ended the session at $1.37, up 42.12% from Thursday's after-hours close, after touching $1.61. Volume was 5,747,267 shares.
- Regular session: Nasdaq paused trading for volatility from 9:38 a.m. to 9:43 a.m. ET. Shares traded between $0.981 and $1.61 and closed at $1.31, down 4.38% from the pre-market close and about 55% above Thursday's close. Volume of 20,551,789 shares was 63.33 times the 10-day average.
- After-hours: the stock slipped another 8.4% to $1.20 on 798,993 shares.
A $161 million stake against a $1 million market value
Regan's case rests on CDT's balance sheet. The letter says CDT reported stockholders' equity of about $103 million at June 30. Its main asset is 1,290 shares of Sarborg Limited, about 22.7% of that company, bought for about $123 million and carried under the equity method (booked at cost adjusted for a share of Sarborg's results, not at market value).
At Sarborg's last investment price, Regan values that stake at about $161 million. He puts CDT's market value at about $1.036 million, using 1,017,864 shares outstanding after the reverse split the company announced Nov. 4. A reverse split combines existing shares into fewer, higher-priced ones.
Corvus has interests on both sides of any deal. Regan says he held 2,064,698 CDT shares, about 22.15%, as of Oct. 23 through his own holding, Corvus and Manoira Limited. He was CDT's chief executive until Aug. 31, 2026, and now runs Sarborg, in which Corvus owns about 43% and most recently bought shares at $125,000 each. Regan wrote that any deal involving him must be negotiated by CDT's independent directors and their own advisers.
Recent financing feeds Regan's complaint
Regan wrote that CDT's shares trade "at a fraction of the value of assets" it owns, and that the company's own financing erodes shareholders' share of Sarborg. In October, CDT filed two such disclosures:
- An Oct. 13 filing reported a material agreement, a new direct financial obligation and unregistered sales of equity securities.
- An Oct. 27 filing reported another material agreement and more unregistered equity sales.
A Nov. 4 filing covered changes to shareholder rights, amendments to the articles or bylaws and a change in fiscal year. The letter also says CDT holders currently have no route to realize the value of the Sarborg stake. Regan listed what would satisfy him instead of a bid: a license deal, development of CDT's pharmaceutical assets or another step that lifts shareholder value.
What comes next for CDT and Corvus
- The board's response. Corvus asked CDT to disclose the letter promptly under Nasdaq rules; CDT had not published a reply by Friday evening.
- A formal proposal, which Corvus said it would make only if the board offers no plan of its own. It set no deadline.
- Any new CDT financing or equity sales, the dilution Regan objects to.
Bottom line
CDT's largest shareholder, who also runs the company's main asset, has put a $2.00 price in front of the board without making an offer. Friday's trading valued that threat well below face value. The next steps rest with the independent directors and with Corvus.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




